Gelonghui, April 18, 丨 China Biotechnology Service (08037.HK) announced that the Hong Kong-Shenzhen Innovation and Technology Park Limited (“Hong Kong-Shenzhen Innovation and Technology Park Corporation”) signed a memorandum of understanding with about 60 partner organizations (including companies), and held the Hong Kong-Shenzhen Innovation and Technology Park partner launch ceremony on April 18, 2024. According to the Memorandum of Understanding between the Company and Hong Kong-Shenzhen Innovation and Technology Park Corporation (collectively referred to as the “parties concerned”), the parties concerned have agreed (among others) to cooperate in the development of the Hong Kong-Shenzhen Innovation and Technology Park in the Lok Ma Chau Hetao area of the Hetao Shenzhen-Hong Kong Science and Technology Cooperation Zone.
The development of boron neutron capture cancer treatment centers and provision of tumor immune cell therapy services are the Group's main business activities. The memorandum of understanding indicates that the company will establish Hong Kong's first boron neutron capture treatment center at the Innovation Park to serve advanced cancer patients in Hong Kong, the Greater Bay Area, Southeast Asia and South Asia in the future. The boron neutron capture therapy equipment and related services will be provided by Sumitomo Heavy Industries, Ltd. (“Sumitomo”) and Stella Pharma Corporation (“Stella Pharma”) in accordance with their respective prior agreements with the Group. The company also acknowledged that Sumitomo and Stella Pharma have each signed memorandums of understanding with Hong Kong-Shenzhen Innovation and Technology Park.
The board believes that by establishing a comprehensive center including the Group's molecular diagnostic laboratory, CAR-T development center and boron neutron capture treatment center, cooperation with the Hong Kong-Shenzhen Innovation and Technology Park Corporation will have a synergistic effect. The integrated center will facilitate the production of the first CD20-targeting autologous CAR-T therapy and the development of boron neutron capture therapy in Hong Kong. The Board further believes that the conclusion of the Memorandum of Understanding is in line with the Government's policy of promoting the development of Hong Kong as a regional scientific research centre and promoting cooperation between the Mainland and Hong Kong.